Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite potential risks like the Keytruda SC litigation and pharma tariffs, Halozyme's strong balance sheet, rising free cash flow, and share buybacks boost EPS and shareholder value.

Diversified Energy Company PLC (OTCQX:DEC) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Douglas Kris - SVP, IR and Corporate Communications Rusty Hutson - Founder and CEO Brad Gray - President and CFO Conference Call Participants Tim Rezvan - KeyBanc Capital Markets Sam Wahab - Peel Hunt Paul Diamond - Citibank Simon Scholes - First Berlin Operator Greetings. Welcome to Diversified Energy's First Quarter 2025 Earnings Conference Call.

The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.

TU's first-quarter 2025 earnings remain flat year over year while revenues grow driven by robust revenues from TTech, TELUS Digital and TELUS Health segments.

RESTON, Va. & WASHINGTON--(BUSINESS WIRE)--OVHcloud, a global full-service cloud provider, announced today during Nutanix's .NEXT conference that it has been awarded the 2025 Global Service Provider Nutanix Partner Award. Nutanix, a leader in hybrid multicloud computing, recognized OVHcloud for its all-in-one and scalable Nutanix® on OVHcloud hyper-converged infrastructure (HCI). OVHcloud helps companies deploy Nutanix Cloud Platform™ (NCP) software licenses on dedicated, Nutanix-qualified OVHc.

Cannabis grower Organigram Holdings Inc OGI reported second-quarter 2025 net sales of $45.7 million (approximately CA$65.6 million). That's up 74% year-over-year, beating the consensus of $42.28 million.

Meta is reportedly considering adopting stablecoins as a way to make cross-border payments. The company is in discussions with crypto firms and is likely to use more than one type of stablecoin, Fortune reported Thursday (May 8), citing unnamed sources.

NORTH BETHESDA, Md. , May 12, 2025 /PRNewswire/ -- Choice Hotels International, Inc. (NYSE: CHH), one of the world's largest lodging franchisors, is proud to announce the release of its 2024 Sustainability Report.

While the top- and bottom-line numbers for HudBay Minerals (HBM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?